Myriad Genetics Inc (MYGN)
Financial leverage ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total assets | US$ in thousands | 1,027,600 | 1,081,300 | 1,085,100 | 1,110,500 | 1,146,500 | 1,149,100 | 1,187,200 | 1,169,300 | 1,198,700 | 1,212,000 | 1,210,200 | 1,255,400 | 1,320,700 | 1,335,900 | 1,360,300 | 1,336,900 | 1,418,800 | 1,444,500 | 1,404,600 | 1,446,700 |
Total stockholders’ equity | US$ in thousands | 701,100 | 731,700 | 740,500 | 760,000 | 783,200 | 683,400 | 735,200 | 835,200 | 885,800 | 916,600 | 947,400 | 950,100 | 967,800 | 968,600 | 902,500 | 875,200 | 879,900 | 909,300 | 918,200 | 967,200 |
Financial leverage ratio | 1.47 | 1.48 | 1.47 | 1.46 | 1.46 | 1.68 | 1.61 | 1.40 | 1.35 | 1.32 | 1.28 | 1.32 | 1.36 | 1.38 | 1.51 | 1.53 | 1.61 | 1.59 | 1.53 | 1.50 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,027,600K ÷ $701,100K
= 1.47
The financial leverage ratio of Myriad Genetics Inc has been fluctuating over the reported periods, ranging from 1.28 to 1.68. A financial leverage ratio of 1 indicates an equal proportion of debt and equity in the company's capital structure.
From March 31, 2020, to September 30, 2021, the ratio showed a general increasing trend, peaking at 1.68 by September 30, 2021, indicating a higher level of financial leverage. This could imply that the company was relying more on debt to finance its operations during this period.
However, from September 30, 2021, to December 31, 2024, the ratio generally decreased, indicating a reduced reliance on debt financing and potentially a stronger equity position compared to previous periods.
Overall, the fluctuation in the financial leverage ratio of Myriad Genetics Inc suggests varying levels of debt and equity utilization in the company's capital structure over the reported periods. Monitoring changes in this ratio is important for assessing the company's risk profile and financial stability.
Peer comparison
Dec 31, 2024